Keynote Address
Moderator: Daniel J. Powell, Jr. PhD – University of Pennsylvania

1:05–1:55 p.m. PT

CAR-T Lessons Learned Guiding Next Gen Cell Therapies 
Kristen M. Hege, MD – Board Member: Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune

Question and Answer

Session I: Next-gen CAR T: Cytokine Engineering
Moderator: Evan W. Weber, PhD – University of Pennsylvania and Children's Hospital of Philadelphia

1:55–3:30 p.m. PT

Anusha Kalbasi, MD – Stanford Medicine

The Development of Engineered, iPSC-derived CAR T cell Therapies
Grant Welstead, PhD – Century Therapeutics

(29) Rational design of orthogonal cytokine immune signaling systems for prototype CAR T cells with reduced cytokine-driven toxicity
Zakaria Dahmani, MSc – University of Pittsburgh

(67) Design of precision-engineered PTPRZ1 CAR T cells to overcome glioblastoma heterogeneity

Aditya Mohan – Duke University

Session II:  Next-gen CAR T: Genetic Engineering to Optimize T cell Fitness 
Moderator: Evan W. Weber, PhD – University of Pennsylvania and Children's Hospital of Philadelphia

3:55–5:30 p.m. PT 

Programmable Signaling Enhances CAR T cell & CAR Macrophage Anti-tumor Activity
Kyle G. Daniels, PhD – Stanford University  

(52) An in vivo human transcription factor overexpression screen to reprogram T cells for effective solid tumor immunotherapy 
Nelson Knudsen, PhD – Broad Institute of MIT and Harvard, Massachusetts General Hospital 

(91) Base editing mediated inactivation of A20ZF7 enhances human CAR T cell antitumor immunity 
Luis R. Sandoval – Gladstone-UCSF Institute of Genomic Immunology, University of California, San Francisco, UC Berkeley – UCSF Graduate Program in Bioengineering 

Session III: Next-gen TILs
Moderator: Kristen M. Hege, MD – Board Member: Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune

8:35–10:10 a.m. PT

Cytokine Engineered TILs - Membrane Bound IL15 Engineered TIL Therapy
Parameswaran Hari, MD – Obsidian Therapeutics 

(2) Translational data validate OBX-115 mechanism of action: impact of dosing on clinical outcome in advanced melanoma
Rodabe Amaria, MD – The University of Texas MD Anderson Cancer Center

(46) Enhanced tumor function with IOV-5001, an autologous tumor-infiltrating lymphocytes (TIL) engineered with inducible membrane-tethered IL-12
Brian R. Gastman, MD, NP – Iovance Biotherapeutics, Inc.

Session IV: Next-gen TCR T cells 
Moderator: Daniel J. Powell, Jr. PhD – University of Pennsylvania

10:35 a.m.–12:15 p.m. PT

Clinical Development of TCR-T cell and Bi-specific T cell Engagers Targeting PRAME+ Cancers
Delfi Krishna, PhD – Immatics Biotechnologies

Session V: In vivo Cell Therapies
Moderator: Kristen M. Hege, MD – Board Member: Mersana, Adaptimmune, Kelonia, KSQ and EvolveImmune

1:25–3:25 p.m. PT

Manufacturing In vivo CAR T-Cell Therapy with Retargeted Lentiviral Vectors
Laura Volta, PhD – University of Pennsylvania

In Vivo CAR-T Cell Therapy with Engineered Lentiviral Vectors: From Concept to Clinic
Philippe Parone, PhD – EsoBiotec

Preclinical Development of an In Vivo Anti-BCMA CAR-T cell Treatment for Multiple Myeloma

(7) Synthetic signaling cascades for CAR mediated in situ macrophage reprogramming
Camillia Azimi, PhD – Icahn School of Medicine at Mount Sinai

(109) In vivo CAR-T T-LNP system (GT801) drives potent B cell depletion and clinical feasibility in hematologic and autoimmune conditions
Pin Wang, PhD – University of Southern California, Grit Biotechnology Inc.

Session VI: Next-gen T cell Engagers
Moderator: Daniel J. Powell, Jr. PhD – University of Pennsylvania

3:50–5:25 p.m. PT

Deepu Madduri, MD – Johnson & Johnson 

Geraldine Paulus, PhD – Crossbow Therapeutics, Inc. 

David B. Weiner, PhD – The Wistar Institute

(17) Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing phase I trial
Olatunji B. Alese, MD, FWACS, FASCO – Winship Cancer Institute of Emory University

(86) A universal, in vivo delivered chimeric adapter protein renders myeloid cells engageable by all CD3-targeting T cell engagers
Kevin Carbajal, PhD – Inceptor Bio

Session VII: Combination Therapies (Oncolytics, Bispecifics, Cytokines, Small Molecule Inhibitors, Epigenetics, TLR Agonists)
Moderator: Gordon Moody – AstraZeneca

8:35–10:10 a.m. PT

Leveraging Synthetic Antigens to Create Universal Immunotherapies for Solid Tumors
Barbra J. Sasu, PhD – Dispatch Biotherapeutics

Engineering CAR T Cells to Secrete T Cell Engagers: Lessons from Immune Monitoring in Clinical Trials
Kathleen Gallagher, PhD – Massachusetts General Hospital

Session VIII: Novel Cell Engineering Approaches 
Moderator: Ashley K. Koegel, MD – Bristol Myers Squibb

10:35 a.m.–12:10 p.m. PT 

10:35–11 a.m.

Advancing In Vivo RNA Therapies Towards Clinical in Oncology
Gilles Besin, PhD – Bristol Myers Squibb

In vivo CAR T Generation: The Future of Cell Therapy
Jacob Garcia, MD – Umoja Biopharma

(37) LTβR armoring reprograms γδ CAR T cells for multifunctional TME resistance and enhanced effector fitness
Theodoros Giavridis, PhD – OverT Bio

(75) Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer
Sangwoo Park, PhD – Massachusetts General Hospital, Harvard Medical School

Session IX: Next-gen Manufacturing 
Moderator: Ashley K. Koegel, MD – Bristol Myers Squibb

1:25–2:50 p.m. PT 

NEX-T Generation Autologous CAR T Cell Process Development: CD19 NEX-T Platform Process Overview
Divya Varun, MS – Bristol Myers Squibb

Meet Total Patient Demand For Cell Therapies with End-to-End Automation
Isabel Tian, PhD – Cellares  

Next-gen iPSC-Derived CAR T cells for Autoimmune Disease and Cancer
Raedun Clarke, PhD – Fate Therapeutics, Inc.